1. Changes of (A) glycated haemoglobin (HbA1c) and (B) estimated glomerular filtration rate (eGFR) in the blood test at baseline and at 3, 6 and 12 months after the initiation of the administration of sodium–glucose cotransporter 2 inhibitor as a systemic medical treatment.
Changes of (A) glycated haemoglobin (HbA1c) and (B) estimated glomerular filtration rate (eGFR) in the blood test at baseline and at 3, 6 and 12 months after the initiation of the administration of sodium–glucose cotransporter 2 inhibitor as a systemic medical treatment.
Hiroki Mieno et al. BMJ Open Ophth 2018;3:e000130
© Author(s) (or their employer(s)) Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.